News for Iterum Therapeutics plc (ITRM)

Iterum Therapeutics (ITRM) grants stock options to new Chief Commercial Officer, Christine Coyne. The options cover 200,000 shares with a $0.97 exercise

DUBLIN and CHICAGO, July 02, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) ('Iterum” or the 'Company”), a company committed to delivering next generation oral and IV antibiotics to address infections caused by multi-drug resistant pathogens, today announced that it has granted a non-statutory share option to purchase an aggregate of 200,000 ordinary shares of Iterum to Christine Coyne, Iterum’s newly appointed Chief Commercial Officer. This grant was awarded pursuant to the Nasdaq inducement grant exception as a component of new hire employment compensation.

**media[651578]**

Iterum Therapeutics (ITRM) has secured an extension from Pfizer regarding the $20 million regulatory milestone payment, now due by October 25, 2029. Originally

Iterum Therapeutics (ITRM) and Pfizer agree to extend a $20M debt payment deadline to October 2029. The interest rate on the debt will increase from 8%

DUBLIN and CHICAGO, May 19, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc ( ITRM) (the ”œCompany” or ”œIterum”), a company focused on delivering next

Total Operating Expenses: $3.7 million in Q1 2025, down from $6.2 million in Q1 2024.R&D Costs: $600,000 in Q1 2025, compared to $4 million in Q1 2024.G&A Cost

May 13, 2025 / 12:30PM GMTOperator Hello, everyone, and thank you for joining the Iterum Therapeutics plc first-quarter 2025 earnings and business update call.

DUBLIN, Ireland and CHICAGO, May 06, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc ( ITRM) (Company), a company focused on delivering next generation oral

DUBLIN, Ireland and CHICAGO, April 30, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc ( ITRM) (the Company), a company focused on delivering next generation

Iterum Therapeutics (ITRM) has finalized an agreement with a single institutional investor to sell 5,555,556 ordinary shares at $0.90 each, in a registered dire

DUBLIN, Ireland and CHICAGO, April 29, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc ( ITRM) (the Company), a company focused on delivering next generation

Maine-based Synergy CHC Corp. (SNYR) is up over 139 percent in Tuesday's pre-market trading. The following are some of the other stocks making big moves in Tuesday's pre-market trading.

On December 31, 2024, ARMISTICE CAPITAL, LLC (Trades, Portfolio) made a significant move by acquiring an additional 105,158 shares of Iterum Therapeutics PLC (I

Operator: Hello, everyone. And welcome to the Iterum Therapeutics plc Fourth Quarter and Full Year 2024 financial results. My name is Ezra, and I will be your coordinator today [Operator Instructions].

Total Operating Expenses (Q4 2024): $3.7 millionTotal Operating Expenses (Full Year 2024): $18.7 millionR&D Costs (Q4 2024): $1.3 millionR&D Costs (Full Year 2

Feb 07, 2025 / 01:30PM GMTOperator Hello, everyone, and welcome to the Iterum Therapeutics PLC Fourth-Quarter and Full Year 2024 Financial Results. My name is E

Iterum Therapeutics plc (NASDAQ:ITRM) Q4 2024 Earnings Conference Call February 7, 2025 8:30 AM ETCompany ParticipantsLouise Barrett - SVP, Legal...

California-based Conduit Pharmaceuticals Inc. (CDT), a clinical-stage specialty biopharmaceutical company is up over 79 percent in Friday's pre-market trading. The following are some of the other stocks making big moves in Friday's pre-market trading.